Rates of irAEs in the Italian Early Access Program of nivolumab in mRCC
| irAEs | G1N (%) | G2N (%) | G3N (%) | G4N (%) | Any gradeN (%) |
|---|---|---|---|---|---|
| Cutaneous | 16 (4) | 12 (3) | 2 (1) | 0 | 30 (8) |
| Endocrine | 10 (3) | 5 (1) | 1 (< 1) | 1 (< 1) | 17 (4) |
| Hepatic | 5 (1) | 2 (1) | 0 | 0 | 7 (2) |
| Gastro-intestinal | 8 (2) | 7 (2) | 4 (1) | 0 | 19 (5) |
| Pulmonary | 1 (< 1) | 1 (< 1) | 2 (1) | 0 | 4 (1) |
Abbreviations: N number, irAEs immune-related adverse events